^
    1d
    YL202-INT-101-01: A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer (clinicaltrials.gov)
    P1, N=80, Active, not recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR mutation • HR positive • HER-2 negative • EGFR L858R • EGFR exon 19 deletion • HR positive + HER-2 negative
    |
    BNT326
    1d
    5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, Peking University Cancer Hospital & Institute
    New trial
    1d
    Beyond BCY: Pregnancy Outcomes After Breast Cancer in Young Women With Germline Pathogenic Variants in Genes Other Than BRCA (clinicaltrials.gov)
    P=N/A, N=2200, Not yet recruiting, Jules Bordet Institute
    New trial
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • BRCA (Breast cancer early onset) • CDH1 (Cadherin 1) • CHEK2 (Checkpoint kinase 2) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1)
    1d
    GO39932: A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer (clinicaltrials.gov)
    P1, N=181, Active, not recruiting, Genentech, Inc. | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • triptorelin • goserelin acetate • giredestrant (RG6171)
    3d
    N01-A-PICIT-GT: Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors (clinicaltrials.gov)
    P2, N=220, Recruiting, Peking University People's Hospital
    New P2 trial
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    3d
    18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Peking University First Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CA9 (Carbonic anhydrase 9)
    4d
    The DIALOGUE Study: Swiss-Korean Billateral Collaboration (clinicaltrials.gov)
    P=N/A, N=128, Completed, University of Basel | Recruiting --> Completed | N=228 --> 128 | Trial primary completion date: May 2025 --> Dec 2025
    Trial completion • Enrollment change • Trial primary completion date
    4d
    Development of immunocompetent models for primary and metastatic ER+ breast cancer. (PubMed, Animal Model Exp Med)
    These findings highlight the potential and limitations of the 129S6/SvEv model as a syngeneic, immunocompetent system for studying ER+ breast cancer metastasis. Reporter expression may affect immunogenicity or cell fitness. Further refinement of these models will enable investigation of immune-modulatory therapies in ER+ metastatic breast cancer.
    Journal • IO biomarker
    |
    ER (Estrogen receptor)
    |
    ER positive
    5d
    Protein Needs Study (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, University of Alberta | Trial completion date: Dec 2025 --> Sep 2030 | Trial primary completion date: Dec 2025 --> Sep 2030
    Trial completion date • Trial primary completion date
    5d
    Emulation of the PALOMA-2 Trial (clinicaltrials.gov)
    P=N/A, N=6097, Completed, Brigham and Women's Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • letrozole
    5d
    A Phase 1 Study of IM-1617 in Participants With Advanced Cancer (clinicaltrials.gov)
    P1, N=175, Not yet recruiting, Immunome, Inc.
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PGR (Progesterone receptor) • PD-1 (Programmed cell death 1)
    |
    HER-2 negative • RAS wild-type
    6d
    Positron-emission tomography as a predictor of response to first-line cyclin-dependent kinase 4/6 inhibitors in patients with metastatic ER-positive HER2-negative breast cancer. (PubMed, NPJ Breast Cancer)
    These findings demonstrate that baseline SUVmax is a strong and readily accessible prognostic biomarker in patients receiving CDK4/6i, helping to identify individuals at elevated risk of early disease progression. Prospective validation is warranted.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive